SNE 101
Alternative Names: SNE-101; SNE-101D; SNE-101M; SNE-101SLatest Information Update: 21 Jul 2025
At a glance
- Originator S&E bio
- Class Anti-inflammatories; Exosome therapies; Mesenchymal stem cell therapies; MicroRNAs; Vascular disorder therapies
- Mechanism of Action Exosome replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Arterial occlusive disorders; Atopic dermatitis; Ischaemic stroke
Most Recent Events
- 21 Jul 2025 SNE 101 is available for licensing as of 21 Jul 2025. http://www.snebio.com/eng/pipeline/pipeline01.asp
- 20 Jul 2025 Preclinical trials in Arterial occlusive disorders in South Korea (IV)) (S&E bio pipeline, July 2025)
- 20 Jul 2025 Preclinical trials in Atopic dermatitis in South Korea (IV) (S&E bio pipeline, July 2025)